United Therapeutics (UTHR) CEO settles 69,579 RSUs with tax withholding

Rhea-AI Filing Summary

United Therapeutics Chairperson and CEO Martine A. Rothblatt reported vesting and settlement of restricted stock units rather than open-market trades. On March 15, 2026, she exercised and converted a total of 69,579 restricted stock units into the same number of common shares on a one-for-one basis.

To cover tax obligations associated with these vestings, 29,196 common shares were withheld by United Therapeutics at $536.12 per share, a non-market tax-withholding disposition. After these transactions, Rothblatt directly held 40,513 shares of common stock, and the filing also shows additional indirect holdings through her spouse and various family trusts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairperson & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		32,499	A	(1)	32,629	D
Common Stock	03/15/2026		M		37,080	A	(1)	69,709	D
Common Stock	03/15/2026		F		13,637(2)	D	$536.12	56,072	D
Common Stock	03/15/2026		F		15,559(2)	D	$536.12	40,513	D
Common Stock								166	I	by Spouse
Common Stock								324,518	I	by Trust(3)
Common Stock								258,117	I	by Trust(4)
Common Stock								45,596	I	by Trust(5)
Common Stock								10,962	I	by Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/15/2026		M			32,499	(7)	(7)	Common Stock	32,499	$0.00	0.00	D
Restricted Stock Units	(1)	03/15/2026		M			37,080	(7)	(7)	Common Stock	37,080	$0.00	0.00	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

2. Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

3. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

4. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

5. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

6. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

7. Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2026.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did United Therapeutics (UTHR) CEO Martine Rothblatt report in this Form 4?

Martine A. Rothblatt reported vesting and settlement of restricted stock units, not open-market trades. She converted 69,579 units into common stock and had shares withheld for taxes, ending with 40,513 shares held directly plus additional indirect family-trust-related holdings.

How many United Therapeutics (UTHR) restricted stock units vested for the CEO?

A total of 69,579 restricted stock units vested and were converted into the same number of United Therapeutics common shares. These units, including performance-based awards, were settled on March 15, 2026, reflecting equity compensation rather than purchases on the open market.

How many United Therapeutics (UTHR) shares were withheld for taxes in this filing?

The company withheld 29,196 United Therapeutics common shares to satisfy tax obligations tied to restricted stock unit vesting. These tax-withholding entries used a price of $536.12 per share and are not considered open-market sales by the CEO.

What is Martine Rothblatt’s direct United Therapeutics (UTHR) shareholding after these transactions?

Following the vesting and tax-withholding events, Martine Rothblatt directly held 40,513 shares of United Therapeutics common stock. The Form 4 also lists additional indirect holdings through her spouse and several family trusts, further increasing her overall economic exposure to the company.

Are there indirect United Therapeutics (UTHR) holdings related to the CEO in this Form 4?

Yes. The filing shows indirect ownership of United Therapeutics shares by the CEO’s spouse and multiple family trusts. Individual entries include 166 shares held by her spouse and several trust positions, such as one trust holding 324,518 shares, reflecting shared and family-related investment power.